Position statement regarding usage of biosimilars: position paper of the Société de néphrologie, Société francophone de dialyse, and Société de néphrologie pédiatrique.
D001688:Biological Products / Q000009:adverse effects / Q000592:standards* / Q000627:therapeutic use; D000068817:Epoetin Alfa; D004921:Erythropoietin / Q000592:standards / Q000627:therapeutic use*; D017408:Guidelines as Topic; D006801:Humans; D011994:Recombinant Proteins; D013810:Therapeutic Equivalency
D001688:Biological Products; D011994:Recombinant Proteins; D004921:Erythropoietin; D000068817:Epoetin Alfa